March 28 (Reuters) - Milestone Pharmaceuticals (MIST.O), opens new tab said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended ... regarding its New Drug Application for Cardamyst nasal spray for the conversion of acute episodes of PSVT ...

Experts have also recommended antihistamine eye drops, like Alaway’s, to SELF before. They work immediately and can give your ...

Milestone Pharmaceuticals MIST recently announced that the FDA ... (“NDA”) seeking approval for CARDAMYST (etripamil) nasal spray. This drug is being developed for the treatment of paroxysmal ...

The nasal mist delivers a drug and steroid-free instant ... You can also find your spray at Walgreens for $10.99. Original price: $109.95 Because allergy season seems to drag on forever, you ...

ITCHY eyes, constant sneezing, a runny nose… all signs hay fever season is well and truly here. Yep, that joyous time of the year when one in four Brits dreads the smell of freshly-cut grass ...

Spring allergies won't derail your plans if you've stocked your home with these 8 picks you can find on Amazon.

MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray ...

Get the next trade alert free. Milestone Pharmaceuticals Inc. MIST announced on Friday that its New Drug Application for CARDAMYST (etripamil) nasal spray, aimed at treating acute episodes of ...